TMEM219 Antibodies Block IGFBP3 Binding for Diabetes Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for inflammatory bowel disease (IBD) and diabetes are limited by adverse effects and questionable long-term efficacy, and there are no commercially available monoclonal antibodies that can prevent the IGFBP3/TMEM219 binding and halt the detrimental effects on target tissues/cells.

Innovation Solution

Development of antibodies that bind with high affinity and specificity to the extracellular domain of TMEM219, inhibiting or reducing the binding of IGFBP3 to its receptor without activating the TMEM219 pathway, thereby providing a therapeutic approach for disorders associated with the IGFBP3/TMEM219 axis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies for IBD and diabetes are used, then treatment is provided, but adverse effects occur and long-term efficacy is questionable

Engineering Contradiction:

Improvelong-term efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces monoclonal antibodies as intermediary substances that specifically bind to TMEM219, blocking the interaction between IGFBP3 and its receptor. This intermediary approach allows therapeutic intervention without directly affecting the complex biological pathways, thereby reducing adverse effects while maintaining long-term efficacy through targeted modulation of the IGFBP3/TMEM219 axis.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If no monoclonal antibodies against TMEM219 are available, then the IGFBP3/TMEM219 axis cannot be targeted, but existing therapies have limited effectiveness

Engineering Contradiction:

Improvetherapeutic targeting capabilityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the therapeutic approach by developing monoclonal antibodies that specifically target the TMEM219 receptor component of the IGFBP3/TMEM219 axis. This segmentation allows independent modulation of the receptor interaction without affecting the entire signaling pathway, thereby enhancing therapeutic versatility and reliability through precise molecular targeting.

Inventive Principle:

Principle #1Segmentation

3Adaptability or versatility

If IGFBP3 binds to TMEM219, then cell growth and apoptosis are regulated, but detrimental effects on target tissues occur

Engineering Contradiction:

Improvebiological regulation functionVSAvoiddetrimental effects on target tissues

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful IGFBP3/TMEM219 binding interaction into a beneficial therapeutic target by developing antibodies that block this interaction. The same biological regulation mechanism that causes detrimental effects is harnessed as a therapeutic strategy, transforming the harmful receptor-ligand interaction into a controllable target for preventing tissue damage and promoting regeneration.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12221485B2TMEM219 antibodies and therapeutic uses thereof

Publication Date: 2025.02.11 ENTHERA SRL

AI summary

The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.